Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRENT TINDAL MCLAURIN

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1740266725
CMS profile
260312
Location
ANDERSON, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,699.55

105 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,688.68 104
Education $10.87 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRENT TINDAL MCLAURIN

NPI 1740266725 · CMS profile ID 260312

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

ANDERSON, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740266725?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRENT TINDAL MCLAURIN, NPI 1740266725, CMS profile ID 260312. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740266725?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). BRENT TINDAL MCLAURIN, NPI 1740266725, CMS profile ID 260312. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740266725?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
BRENT TINDAL MCLAURIN, NPI 1740266725, CMS profile ID 260312, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 105 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1740266725?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

105 matching records · $1,699.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 105 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 105.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
CARDIVA MEDICAL, INC. $18.4107/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839387619 CMS
Novartis Pharmaceuticals Corporation $17.8807/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813070839 CMS
Abbott Laboratories $22.9907/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833739847 CMS
Abbott Laboratories $15.4507/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833739827 CMS
Abbott Laboratories $15.2507/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833739834 CMS
Abbott Laboratories $15.4207/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833739841 CMS
PFIZER INC. $13.2306/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832552701 CMS
W. L. Gore & Associates, Inc. $22.7606/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844711631 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.3106/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763341216 CMS
E.R. Squibb & Sons, L.L.C. $19.2506/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783507151 CMS
Abbott Laboratories $24.4806/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815531271 CMS
Novartis Pharmaceuticals Corporation $22.9706/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813070835 CMS
Merck Sharp & Dohme Corporation $13.4206/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848489403 CMS
Abbott Laboratories $3.7305/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815503815 CMS
Abbott Laboratories $14.2005/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815503819 CMS
Sientra, Inc. $110.2905/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853215839 CMS
Abbott Laboratories $20.1005/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815500000 CMS
AstraZeneca Pharmaceuticals LP $12.2805/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830024385 CMS
AstraZeneca Pharmaceuticals LP $13.5205/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829537947 CMS
Novartis Pharmaceuticals Corporation $18.1005/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813070831 CMS
Abbott Laboratories $15.1205/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815633433 CMS
CARDIVA MEDICAL, INC. $28.4405/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839387623 CMS
Merck Sharp & Dohme Corporation $17.4605/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848725249 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $10.6905/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768788666 CMS
AstraZeneca Pharmaceuticals LP $13.6204/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829705499 CMS
Merck Sharp & Dohme Corporation $17.1104/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848407797 CMS
Merck Sharp & Dohme Corporation $10.8704/27/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848725125 CMS
Amgen Inc. $11.5404/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825187863 CMS
Abbott Laboratories $15.2704/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815470143 CMS
Novartis Pharmaceuticals Corporation $13.2704/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813070827 CMS
Abbott Laboratories $17.1004/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815464597 CMS
Abbott Laboratories $23.4004/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815462237 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.9604/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763341218 CMS
Medtronic, Inc. $12.4604/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815742129 CMS
Merck Sharp & Dohme Corporation $9.4203/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848600153 CMS
Abbott Laboratories $12.9403/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818447569 CMS
Abbott Laboratories $14.2703/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818440505 CMS
Abbott Laboratories $15.5003/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818440507 CMS
Abbott Laboratories $15.5103/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818440509 CMS
Abbott Laboratories $16.0703/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818440511 CMS
Novartis Pharmaceuticals Corporation $19.0703/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813070819 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $10.8603/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768788664 CMS
Amgen Inc. $12.5003/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825187859 CMS
Abbott Laboratories $18.6703/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818432205 CMS
CARDIVA MEDICAL, INC. $20.5903/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839387543 CMS
Merck Sharp & Dohme Corporation $10.5003/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848406667 CMS
AstraZeneca Pharmaceuticals LP $14.9002/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830005603 CMS
Amgen Inc. $14.4602/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825187855 CMS
Amgen Inc. $15.9401/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825187851 CMS
ARBOR PHARMACEUTICALS, INC. $17.9401/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830927471 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,004.05 116
PY2020 $1,333.97 79
PY2021 $1,699.55 105
PY2022 $1,406.10 96
PY2023 $1,833.25 122
PY2024 $1,739.56 100
PY2025 $772.34 46

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $65,441.47 45
PY2024 Principal investigator $111,372.27 84
PY2023 Principal investigator $167,770.84 128
PY2022 Principal investigator $37,209.14 137
PY2021 Principal investigator $100,233.70 96
PY2020 Principal investigator $208,641.93 308
PY2019 Principal investigator $360,533.04 119

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Medtronic, Inc. $9,752.97 12/31/2025 Non-covered Recipient Entity
Anmed/Iva Medical Center
SPYRAL AFFIRM No dispute reported 06/30/2026 1185006568
Principal investigator 1 Janssen Research & Development, LLC $1,662.00 12/12/2025 Covered Recipient Teaching Hospital
Anmed Health
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175269050
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 12/01/2025 Covered Recipient Teaching Hospital
Anmed Health
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175388544
Principal investigator 1 Abbott Laboratories $642.00 11/24/2025 Covered Recipient Teaching Hospital
Anmed Health
NCT05423379--XIENCE Skypoint Large Vessel Post Approval Study No dispute reported 06/30/2026 1248159898
Principal investigator 1 Janssen Research & Development, LLC $3,324.00 11/19/2025 Covered Recipient Teaching Hospital
Anmed Health
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175268954
Principal investigator 1 Janssen Research & Development, LLC $784.00 11/07/2025 Covered Recipient Teaching Hospital
Anmed Health
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175268984
Principal investigator 1 Janssen Research & Development, LLC $434.00 11/03/2025 Covered Recipient Teaching Hospital
Anmed Health
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175269071
Principal investigator 1 Abbott Laboratories $135.00 10/22/2025 Covered Recipient Teaching Hospital
Anmed Health
NCT04227899--LIFE-BTK Randomized Controlled Trial No dispute reported 06/30/2026 1248158384
Principal investigator 1 Abbott Laboratories $202.00 09/25/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT05423379--XIENCE Skypoint Large Vessel Post Approval Study No dispute reported 06/30/2026 1248156812
Principal investigator 1 Janssen Research & Development, LLC $2,782.00 09/19/2025 Covered Recipient Teaching Hospital
Anmed Health
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175268932
Principal investigator 1 Janssen Research & Development, LLC $4,500.00 09/03/2025 Covered Recipient Teaching Hospital
Anmed Health
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) No dispute reported 06/30/2026 1175268944
Principal investigator 1 Janssen Research & Development, LLC $4,822.00 08/25/2025 Covered Recipient Teaching Hospital
Anmed Health
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175269115
Principal investigator 1 Abbott Laboratories $2,090.00 07/31/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT05423379--XIENCE Skypoint Large Vessel Post Approval Study No dispute reported 06/30/2026 1248153598
Principal investigator 1 Janssen Research & Development, LLC $2,390.00 07/23/2025 Covered Recipient Teaching Hospital
Anmed Health
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175268992
Principal investigator 1 Janssen Research & Development, LLC $766.00 07/18/2025 Covered Recipient Teaching Hospital
Anmed Health
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175388515
Principal investigator 1 Janssen Research & Development, LLC $346.00 07/18/2025 Covered Recipient Teaching Hospital
Anmed Health
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175388521
Principal investigator 1 Medtronic, Inc. $272.00 07/09/2025 Covered Recipient Teaching Hospital
Anmed Health
SPYRAL AFFIRM No dispute reported 06/30/2026 1192324903
Principal investigator 1 Janssen Research & Development, LLC $392.00 06/23/2025 Covered Recipient Teaching Hospital
Anmed Health
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175268904
Principal investigator 1 Janssen Research & Development, LLC $2,390.00 06/20/2025 Covered Recipient Teaching Hospital
Anmed Health
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175268923
Principal investigator 1 Janssen Research & Development, LLC $1,915.00 06/09/2025 Covered Recipient Teaching Hospital
Anmed Health
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175269129
Principal investigator 1 Janssen Research & Development, LLC $2,575.00 05/21/2025 Covered Recipient Teaching Hospital
Anmed Health
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175269044
Principal investigator 1 Abbott Laboratories $916.00 05/14/2025 Covered Recipient Teaching Hospital
Anmed Health
NCT05423379--XIENCE Skypoint Large Vessel Post Approval Study No dispute reported 06/30/2026 1248150982
Principal investigator 1 Abbott Laboratories $436.00 04/23/2025 Covered Recipient Teaching Hospital
Anmed Health
NCT05423379--XIENCE Skypoint Large Vessel Post Approval Study No dispute reported 06/30/2026 1248150150
Principal investigator 1 Janssen Research & Development, LLC $2,386.00 04/23/2025 Covered Recipient Teaching Hospital
Anmed Health
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175269107
Principal investigator 1 Janssen Research & Development, LLC $2,782.00 03/21/2025 Covered Recipient Teaching Hospital
Anmed Health
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175269123
Principal investigator 1 Medtronic, Inc. $830.00 03/19/2025 Covered Recipient Teaching Hospital
Anmed Health
SPYRAL AFFIRM No dispute reported 06/30/2026 1192324901
Principal investigator 1 Abbott Laboratories $1,567.00 03/11/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT04227899--LIFE-BTK Randomized Controlled Trial No dispute reported 06/30/2026 1248147518
Principal investigator 1 Janssen Research & Development, LLC $4,547.00 02/19/2025 Covered Recipient Teaching Hospital
Anmed Health
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175269028
Principal investigator 1 Abbott Laboratories $159.00 01/24/2025 Non-covered Recipient Entity
WCG Clinical, Inc
NCT04227899--LIFE-BTK Randomized Controlled Trial No dispute reported 06/30/2026 1248145878
Principal investigator 1 Medtronic, Inc. $3,628.00 01/24/2025 Covered Recipient Teaching Hospital
Anmed Health
SPYRAL AFFIRM No dispute reported 06/30/2026 1192324899
Principal investigator 1 Janssen Research & Development, LLC $2,782.00 01/22/2025 Covered Recipient Teaching Hospital
Anmed Health
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175268978
Principal investigator 1 BIOTRONIK INC. $240.00 01/14/2025 Covered Recipient Teaching Hospital
Anmed Health
BIOFLOW-VII No dispute reported 06/30/2026 1244363133
Principal investigator 1 BIOTRONIK INC. $267.50 01/14/2025 Covered Recipient Teaching Hospital
Anmed Health
BIOFLOW-VII No dispute reported 06/30/2026 1244363135
Principal investigator 1 BIOTRONIK INC. $240.00 01/14/2025 Covered Recipient Teaching Hospital
Anmed Health
BIOFLOW-VII No dispute reported 06/30/2026 1244363137
Principal investigator 1 BIOTRONIK INC. $48.75 01/14/2025 Covered Recipient Teaching Hospital
Anmed Health
BIOFLOW-VII No dispute reported 06/30/2026 1244363139
Principal investigator 1 BIOTRONIK INC. $101.25 01/14/2025 Covered Recipient Teaching Hospital
Anmed Health
BIOFLOW-VII No dispute reported 06/30/2026 1244363141
Principal investigator 1 BIOTRONIK INC. $48.75 01/14/2025 Covered Recipient Teaching Hospital
Anmed Health
BIOFLOW-VII No dispute reported 06/30/2026 1244363143
Principal investigator 1 BIOTRONIK INC. $101.25 01/14/2025 Covered Recipient Teaching Hospital
Anmed Health
BIOFLOW-VII No dispute reported 06/30/2026 1244363145
Principal investigator 1 BIOTRONIK INC. $48.75 01/14/2025 Covered Recipient Teaching Hospital
Anmed Health
BIOFLOW-VII No dispute reported 06/30/2026 1244363147
Principal investigator 1 BIOTRONIK INC. $101.25 01/14/2025 Covered Recipient Teaching Hospital
Anmed Health
BIOFLOW-VII No dispute reported 06/30/2026 1244363149
Principal investigator 1 BIOTRONIK INC. $48.75 01/14/2025 Covered Recipient Teaching Hospital
Anmed Health
BIOFLOW-VII No dispute reported 06/30/2026 1244363151
Principal investigator 1 BIOTRONIK INC. $101.25 01/14/2025 Covered Recipient Teaching Hospital
Anmed Health
BIOFLOW-VII No dispute reported 06/30/2026 1244363153
Principal investigator 1 BIOTRONIK INC. $235.00 01/14/2025 Covered Recipient Teaching Hospital
Anmed Health
BIOFLOW-VII No dispute reported 06/30/2026 1244363155
Principal investigator 1 BIOTRONIK INC. $48.75 01/14/2025 Covered Recipient Teaching Hospital
Anmed Health
BIOFLOW-VII No dispute reported 06/30/2026 1244363157
Principal investigator 1 BIOTRONIK INC. $101.25 01/14/2025 Covered Recipient Teaching Hospital
Anmed Health
BIOFLOW-VII No dispute reported 06/30/2026 1244363159